Overview

A Study for AR100DP1 in Atopic Dermatitis (AD)

Status:
Not yet recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

This is a Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Subjects with Atopic Dermatitis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Arjil Pharmaceuticals LLC

Treatments:

Iclaprim